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Objective: The potassium channel opener, pinacidil, has been shown to be an
effective cardioplegic agent over short periods of ischemia. However,
clinical settings typically involve longer ischemic periods. This study tested
the hypothesis that myocardial protection with a potassium channel opener
is feasible during prolonged periods of arrest and is comparable with the
traditional St. Thomas’ Hospital solution. Methods: With a blood-perfused,
isolated rabbit heart model, hearts underwent 1 hour of global normother-
mic ischemia followed by 30 minutes of reperfusion. During ischemia, three
different cardioplegic solutions were administered either intermittently by
infusion every 20 minutes or as continuous low-flow cardioplegia (150 ml
total volume in all groups): (1) Krebs-Henseleit solution alone (control),
(2) Krebs-Henseleit solution 1 pinacidil (50 mmol/L), or (3) St. Thomas’
Hospital solution. Initial potassium channel opener infusions contained 5
mmol/L procaine. Postreperfusion systolic function (percent of developed
pressure) was measured. Compliance changes were integrated from the
end-diastolic pressure/volume relationships. Results: For intermittent car-
dioplegia, only St. Thomas’ Hospital solution improved function (62.5% 6
4.0%) versus control (43.6% 6 3.3%, p < 0.001). However, with continuous
cardioplegia, only pinacidil (75.6% 6 4.8%) exceeded control (62.7% 6
2.2%, p < 0.001) and was significantly better than St. Thomas’ Hospital
solution. Compared with the intermittent control group, all other groups
showed significant preservation of preischemic diastolic properties. Con-
clusions: Myocardial protection during a longer, more clinically relevant
ischemic period is feasible with a potassium channel opener only when it is
given continuously. Continuous low-flow pinacidil cardioplegia was supe-
rior to St. Thomas’ Hospital solution given either as an intermittent or
continuous infusion. (J Thorac Cardiovasc Surg 1998;116:131-8)
Potassium cardioplegia has been the foundationof myocardial protection for the last quarter of a
century. Conventional hyperkalemic solutions depo-
larize the cell membrane to induce rapid electrome-
chanical arrest, thereby markedly reducing cellular
energy expenditure during the ischemic period.
However, despite acceptable results, depolarizing
solutions possess fundamental shortcomings. So-
dium influx during arrest activates sodium-calcium
exchangers, which, along with calcium leak from the
sarcoplasmic reticulum, contribute to intracellular
calcium overload.1, 2 The altered cellular environ-
ment provokes compensatory metabolic processes,
notably activation of sodium and calcium ion pumps,
which expend energy reserves in the ischemic cell.2, 3
These ionic and metabolic disturbances have been
implicated as etiologic factors in many pathologic
processes including activation of catabolic enzyme
systems, abnormal regulation of intracellular second
messengers, myocardial stunning, calcium-activated
arrhythmogenic currents, and myocardial edema.4-7
It is our hypothesis that the ideal cardioplegic
solution should produce readily reversible, rapid
electromechanical arrest while arresting the myo-
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cyte near its natural, resting membrane potential. At
these “hyperpolarized” potentials, transmembrane
ion gradients are balanced and metabolic demand is
minimal. Also, an ideal agent should take advantage
of the myocyte’s intrinsic cardioprotective response
to ischemia.
In 1983, cardiac cells were discovered to contain a
unique class of metabolically linked potassium chan-
nels that possess intrinsic cardioprotective proper-
ties.8 These adenosine triphosphate (ATP)–sensi-
tive potassium channels were shown to open during
cellular ischemia. The potassium efflux caused ac-
tion potential shortening, decreased calcium influx,
and subsequent contractile failure, which consti-
tuted an intrinsic energy-sparing mechanism during
ischemia.9
ATP-sensitive potassium channels are activated
by a diverse group of pharmacologic agents collec-
tively called potassium channel openers (PCOs).
Previous work in our laboratory has shown PCOs to
be effective cardioplegic agents that adequately pro-
tect the myocardium during global ischemia.10-13
However, these studies involved only short periods
of surgical ischemia. Clinical settings typically in-
volve longer ischemic periods. The present study
tested the hypothesis that myocardial protection
with a PCO is feasible during prolonged periods of
arrest and is comparable to the traditional hyperka-
lemia St. Thomas’ Hospital cardioplegic solution.
Methods
Adult New Zealand White rabbits of either sex, weigh-
ing 2.8 to 3.1 kg, were used in this study. All animals
received humane care in American Association for the
Accreditation of Laboratory Animal Care–approved,
United States Department of Agriculture–registered (No.
23-R-02) facilities in compliance with the “Principles of
Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute
of Laboratory Animal Resources and published by the
National Institutes of Health (NIH Publication No. 86-23,
revised 1985.)
Experimental preparation
Preparation of the support animal. The support animal
was anesthetized, attached to a ventilator, and given
heparin as previously described.13
The right femoral artery was cannulated; the cannula
was connected to a pressure transducer (model P231D;
Gould Inc., Cleveland, Ohio), and continuous invasive
monitoring (Sirecust 404-1A; Siemens Medical Systems,
Inc., Danvers, Mass.) of blood pressure was begun. A
systolic blood pressure above 80 mm Hg was maintained
by transfusion of either blood collected from the donor
animal or Plasma-Lyte electrolyte solution (Baxter
Healthcare Corp., Deerfield, Ill.).
The left internal jugular vein and the left carotid artery
were cannulated. Cannulas were attached to silicone
rubber tubing (internal diameter 5 0.125 inch; Baxter
Scientific Products, McGaw Park, Ill.) and positioned in
roller pumps. Arterial blood was pumped (Masterflex
model 7013; Cole Parmer Inst. Co., Chicago, Ill.) to
perfuse a modified Langendorff apparatus described pre-
viously (Fig. 1).12 Column height was 80 cm. Effluent from
the column was returned to the internal jugular vein of the
support animal. Indomethacin (1 mg/gm) (INN: indo-
metacin) was administered to the support animal to
augment blood pressure stability.14
Preparation of the donor animal and isolated heart. The
donor animal was anesthetized, intubated, attached to a
ventilator, and given heparin.13 A rapid cardiectomy was
accomplished through a median sternotomy. The aorta
was cannulated with the heart suspended from a modified
Langendorff apparatus, and blood perfusion was begun. A
fluid-filled latex balloon was placed into the left ventricle
and secured with a purse-string suture in the mitral valve
anulus. The balloon was connected via polyethylene tub-
ing to a pressure transducer (model P231D; Gould Inc.)
and amplifier (model 13-4615-50; Gould Inc.). The zero-
pressure reference was set at the level of the aortic valve.
Two needle electrodes were secured in the right atrial
appendage and connected to a pacemaker (model 5320;
Medtronic, Inc., Minneapolis, Minn.); the heart rate was
maintained at a constant rate of 180 to 240 beats/minute.
Two additional electrodes were placed on the left ventric-
ular epicardium to monitor the bipolar ventricular elec-
trogram. The electrodes were connected to an isolated
preamplifier (model 11-G5407-58; Gould Inc.) and a
universal amplifier (model 13-4615-58; Gould Inc.) and
filtered between 0.05 and 1000 Hz. The pressure and
electrogram waveforms were displayed continuously and
Fig. 1. Schematic diagram of the parabiotic isolated
heart apparatus. LV, Left ventricular.
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digitized in real time with a WINDAQ/200 system
(DATAQ Instruments, Akron, Ohio) at a sampling rate of
1000 Hz. Coronary flow was measured with an in-line flow
probe and continuously monitored with a flowmeter
(model T206; Transonic Systems, Inc., Ithaca, N.Y.).
The heart was enclosed in a water-jacketed beaker, and
myocardial temperature was measured with a probe
placed in the right ventricle (model BAT 8; Bailey Instru-
ments, Saddle Brook, N.J.). Myocardial temperature was
maintained at 37° C by adjusting the temperature of the
water bath (model D1; Haake Co., Berlin, Germany).
Experimental protocol. Hearts that did not generate a
systolic pressure exceeding 80 mm Hg at an end-diastolic
pressure (EDP) of 10 mm Hg were excluded from the
study. After instrumentation, hearts were given 30 min-
utes to equilibrate. Baseline data were acquired. Intracav-
itary left ventricular pressure waveforms and left ventric-
ular bipolar electrograms were recorded over seven
balloon volumes, each corresponding to a fixed intracav-
itary EDP (0, 2.5, 5, 10, 15, 20, and 25 mm Hg). Hearts
were randomized to undergo cardioplegic infusion by one
of seven modes before the onset of 60 minutes of global
ischemia (32° to 34° C). The groups were divided into
those receiving intermittent cardioplegia and those receiv-
ing continuous cardioplegia. In the intermittent group, 50
ml of cardioplegic solution was given every 20 minutes. In
the hearts receiving continuous cardioplegia, a 50 ml bolus
of cardioplegic solution was followed by a continuous
infusion of 1.67 ml/min (infusion pump model Minipulse
2; Gilson, Middleton, Wis.) for a total of 100 ml delivered
continuously over the ischemic period. The total amount
of cardioplegic solution delivered was identical in the
intermittent and continuous groups. For each infusion
group, hearts received one of three different cardioplegic
regimens: (1) control solution consisting of Krebs-Hense-
leit solution alone (n 5 6); (2) hyperkalemic cardioplegia
with St. Thomas’ Hospital solution (n 5 6); or (3)
hyperpolarizing cardioplegia with 50 mmol/L of pinacidil
(continuous, n 5 6; intermittent, n 5 8). The delivery
medium for pinacidil cardioplegic solutions was Krebs-
Henseleit solution (NaCl 118.5 mmol/L, NaHCO3 25
mmol/L, KCl 3.2 mmol/L, MgSO4, 1.2 mmol/L, KH2PO4
1.2 mmol/L, CaCl2 2.5 mmol/L, and glucose 5.5 mmol/L).
Prolonged electromechanical activity with pinacidil car-
dioplegia has been documented in our laboratory.13 Pre-
vious studies from our laboratory have shown that this
persistent electromechanical activity can be reversibly
eliminated with sodium channel blockade using 5 mmol/L
procaine.15 Therefore, the initial pinacidil infusion con-
tained 5 mmol/L procaine. A separate group was treated
with intermittent boluses of 50 mmol/L pinacidil and was
administered procaine in all doses (5 mmol/L at 0 min-
utes, 2 mmol/L at 20 minutes and 40 minutes; n 5 4) to
eliminate transient electromechanical activity during rein-
fusion and to determine whether procaine augmented
PCO cardioprotection during prolonged ischemia. Pinaci-
dil was provided by Leo Pharmaceuticals, Billup, Den-
mark. St. Thomas’ Hospital solution (Plegisol; Na 110
mEq/L, Cl 160 mEq/L, K 16 mEq/L, Ca 2.4 mEq/L, Mg 32
mEq/L) was provided by Abbott Laboratories, Chicago,
Illinois.
After 1 hour of global ischemia, hearts were reperfused
for 30 minutes. The heart was defibrillated, if necessary.
Intracavitary left ventricular pressure waveforms and elec-
trograms were recorded over the identical range of bal-
loon volumes recorded during baseline data acquisition.
At the conclusion of the study, a sample of the left
ventricle was excised, blotted, weighed, and dried until a
constant dry weight was reached. Myocardial edema was
expressed as the percent tissue water in the following
equation:
%H2O 5 ~Wet weight – Dry weight!/Wet weight (1)
Data analysis
End-systolic pressure. The end-systolic pressure (ESP)
of a beat was defined and averaged as previously de-
scribed.10-13 Mean ESP was calculated for each of the
seven baseline and seven postreperfusion balloon vol-
umes. ESP versus volume data were fitted to a linear
ESP-volume relationship (ESPVR) with a least-squares
linear regression:
ESP 5 Emax 3 V 1 k (2)
where Emax is the slope of the ESPVR, V is the volume,
and k is the y-axis intercept of the ESPVR.
End-diastolic pressure. The EDP of a beat was deter-
mined and averaged for 10 consecutive beats to calculate
the mean EDP.13 The EDP versus volume data were fitted
to a linear EDP-volume relationship with a least-squares
linear regression:
EDP 5 m~V 2 V0! (3)
where m is the slope of the EDP-volume relationship, V is
the volume, and V0 is the balloon volume at which EDP is
zero, or the x-axis intercept.16, 17
Developed pressure. Developed pressure in the left ven-
tricle (DP) was defined as the difference between ESP and
EDP for a given beat. The DP of 10 beats was averaged
Table I. Times to mechanical and electrical arrest
Intermittent cardioplegia Continuous cardioplegia
Control
(n 5 6)
Pin
(n 5 8)
Pin/pro
(n 5 4)
St. T
(n 5 6)
Control
(n 5 6)
Pin
(n 5 6)
St. T
(n 5 6)
EA (sec) 1788 6 435 30 6 2* 31 6 1* 48 6 8* 3101 6 388 50 6 9* 47 6 7*
MA (sec) 587 6 108 31 6 6* 34 6 4* 42 6 7* 2928 6 382 45 6 8* 55 6 11*
Results are expressed as mean 6 SEM. Control, K-H solution only; pin, pinacidil cardioplegia; pin/pro, procaine added to all doses of pinacidil; St. T, St.
Thomas’ Hospital cardioplegia; EA, electrical arrest; MA, mechanical arrest.
*Statistically different from both controls (analysis of variance, p , 0.001).
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for each balloon volume. The DP versus volume data were
fitted to a linear pressure-volume relationship with the
following regression:
DP 5 ESP – EDP 5 ~Emax 3 V 1 k! – m~V – V0! (4)
Recovery of DP. The recovery of DP, expressed as a
percentage, was calculated as the ratio of the postreper-
fusion developed pressure to the mean baseline developed
pressure at the same balloon volume. The average percent
recovery of developed pressure (%DP) was determined
using the trapezoidal rule as described previously.18
Diastolic compliance. Because this model incorporates
a wide range of volumes to establish functional parame-
ters over an entire pressure-volume relationship, changes
in compliance at a single, fixed volume were validated by
analyzing an integrated spectrum of diastolic changes.
Integrated areas of the left ventricular end-diastolic pres-
sure (LVEDP)–volume relationships were calculated and
expressed as a ratio of baseline to after reperfusion. The
mean LVEDP ratio was determined with the following
definite integral:
Mean LVEDP ratio 5E
Va
Vb
Pb
Pr
dV/(Vb2Va) (5)
where Vb is the largest matching postreperfusion balloon
volume, Va is the smallest matching postreperfusion bal-
loon volume, Pb is LVEDP at baseline, and Pr is the
LVEDP after reperfusion. A ratio of 1 therefore reflects
no change in diastolic compliance.
Statistical analysis. Results are expressed as the
mean 6 standard error of the mean. Analysis of variance
was used for multiple comparisons. When appropriate,
the Kruskal-Wallis analysis of variance on ranks was used
as a nonparametric alternative. Pairwise comparisons
between groups were made with a Student-Newman-
Keuls post test. Comparisons to a single control value
were made with a Dunnett’s post-test. A t test was used for
comparisons between two sets, with a Mann-Whitney rank
sum test as a nonparametric alternative. A x2 analysis of
contingency tables was used to compare mutually exclu-
sive, categoric data where appropriate.
Results
There were no significant differences in pH, oxy-
gen tension, carbon dioxide tension, serum sodium,
potassium, calcium, or hematocrit in the support
animal between baseline data acquisition and after
30 minutes of reperfusion. Furthermore, there were
no significant differences in postischemic systolic
function, diastolic compliance, onset of electrome-
chanical arrest, or tissue water content between the
Fig. 2. Postischemic systolic function expressed as the percent recovery of left ventricular developed
pressure (%DP), grouped by method of cardioplegic infusion. All results are expressed as mean 6 SEM.
Pinacidil/procaine means that procaine was added to all infusions. Statistically significant difference by
one-way analysis of variance (p , 0.001) versus intermittent St. Thomas’ Hospital solution (*), continuous
St. Thomas’ Hospital solution (†), respective control (‡), or all other groups (§). K-H, Krebs Henseleit.
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intermittent pinacidil groups with and without the
additional procaine doses.
Temporal aspects of the development of electro-
mechanical arrest. All pinacidil and St. Thomas’
Hospital groups demonstrated significantly shorter
times to electrical arrest over controls (Table I).
There were no significant differences in times to
electromechanical arrest between PCO and St.
Thomas’ Hospital solutions. Of the hearts treated
with continuous, slow infusion of Krebs-Henseleit
solution only, mechanical and electrical activity
persisted throughout the entire ischemic period
for 50% and 67% of the hearts, respectively.
Transient return of low-amplitude electrical activ-
ity was usually observed after pinacidil infusion at
20 and 40 minutes of ischemia. This effect was not
observed when 2 mmol/L procaine was added to
the infusate.
Reperfusion arrhythmias. Only two of 42 hearts
comprising this study exhibited ventricular fibrilla-
tion on reperfusion (pinacidil, one continuous and
one intermittent). These were electrically converted
to sinus rhythm. There were no statistically signifi-
cant differences between groups in the incidence of
reperfusion ventricular fibrillation.
Postischemic systolic function. Cardioplegia with
continuous low-dose pinacidil resulted in improved
recovery compared with control and St. Thomas’
Hospital cardioplegia, regardless of the method of
infusion (Fig. 2). However, intermittent pinacidil
cardioplegia was ineffective, showing no improve-
ment over the control group. Unlike pinacidil, the
protective effects of St. Thomas’ Hospital solution
were not altered by the method of infusion.
Postischemic diastolic compliance. Changes in
diastolic compliance were measured with a fixed-
volume comparison (Table II). LVEDP was com-
pared at an identical, fixed balloon volume at base-
line and after reperfusion. The fixed volume
corresponded to a baseline LVEDP of 5 mm Hg. No
statistical differences in baseline values were shown
between groups. However, after reperfusion, the
intermittent control group showed a significantly
higher mean LVEDP than all other groups. There
were no differences in compliances between any of
the cardioplegia groups.
The fixed-volume comparison was validated by
an alternative analysis that compared the entire
range of matched volumes. Integrated areas of the
diastolic pressure-volume relationships, expressed
as a ratio of baseline to postreperfusion, were
calculated. A baseline-to-postreperfusion mean
LVEDP ratio of 1 reflected no change in diastolic
compliance (Table II). Compared with the inter-
mittent-infusion control group, all other groups
demonstrated significant preservation of baseline
diastolic compliance, in agreement with the single
fixed-volume analysis.
Coronary flow. All groups exhibited a significant
increase in coronary flow immediately on reperfu-
sion. Unlike St. Thomas’ Hospital cardioplegia,
pinacidil produced a prolonged hyperemic state on
reperfusion (Fig. 3). These patterns were not signif-
icantly affected by the method of infusion.
Myocardial tissue water. The mean percent tis-
sue water for the seven groups was as follows:
intermittent Krebs-Henseleit solution (control),
80.4% 6 0.4%; continuous slow Krebs-Henseleit
solution (continuous control), 79.6% 6 1.0%;
pinacidil, 78.9% 6 0.4%; pinacidil/procaine (all
doses), 79.3% 6 0.4%; pinacidil, continuous low-
dose infusion, 78.5% 6 0.4%; St. Thomas’ Hospital
solution, 79.7% 6 0.2%; and St. Thomas’ Hospital
solution continuous infusion, 78.4% 6 0.5%. No
significant differences in tissue water content were
detected among the groups.
Table II. Postischemic LVEDP measured by the fixed volume comparison and validated by integration of
LVEDP versus volume relationships before and after ischemia
Intermittent cardioplegia Continuous cardioplegia
Control
(n 5 6)
Pin
(n 5 8)
Pin/pro
(n 5 4)
St. T
(n 5 6)
Control
(n 5 6)
Pin
(n 5 6)
St. T
(n 5 6)
LVEDP5 (mm Hg) 31.2 6 12.1 4.8 6 0.9* 4.8 6 1.7* 4.3 6 0.4* 6.0 6 1.4* 7.2 6 3.1* 5.3 6 0.5*
d(Pb/Pr)dV 0.42 6 0.17 1.00 6 0.08* 1.09 6 0.23* 1.04 6 0.07* 0.82 6 0.10* 0.86 6 0.23* 0.98 6 0.06*
Results are expressed as mean 6 SEM. Control, K-H solution; pin, pinacidil; pin/pro, pinacidil, intermittent infusion/procaine in all three doses; St T, St.
Thomas’ solution; LVEDP5, postreperfusion LVEDP at identical volume corresponding to baseline LVEDP of 5 mm Hg; d(Pb/Pr)dV, definite integral of the
baseline to postreperfusion LVEDP versus volume relationships; Pb, LVEDP at baseline; Pr, LVEDP after reperfusion, respectively. A ratio of 1 reflects no
diastolic change.
*Statistically different from intermittent control (analysis of variance, p 5 0.003 for LVEDP5; p 5 0.006 for d[Pb/Pr]dV).
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Discussion
Principles of hyperpolarized arrest. The cardiac
cell is hyperpolarized at rest. PCOs, which hyperpo-
larize the membrane, theoretically minimize ongo-
ing metabolic activity that can lead to ischemic
injury by approximating the resting state of the
myocyte. Under these circumstances, transmem-
brane ionic gradients are balanced, ion channel flux
minimal, and ATP-driven pumps largely inactive.19
Our laboratory has shown that PCO cardioplegia
was either better than or as protective as the tradi-
tional St. Thomas’ Hospital cardioplegia over short
ischemic periods.10, 12, 13 However, the clinically rel-
evant question of whether hyperpolarized arrest is
cardioprotective during prolonged periods of isch-
emia had not been investigated before this study.
Recent efforts to optimize myocardial protection
during cardioplegic arrest have focused on normo-
thermic continuous or near-continuous infusion of
standard depolarizing solutions. This avoids the
theoretically detrimental aspects of hypother-
mia20-24 and provides a continuous supply of sub-
strate and oxygen during electromechanical arrest,
potentially abolishing ischemia and minimizing
reperfusion injury.21, 22 However, current tech-
niques of continuous normothermic cardioplegia
have several shortcomings, including the need for
large volumes, high potassium loads, and difficulty
visualizing the operative field.24 It is our hypothesis
that hyperpolarizing cardioplegic solutions may
solve some of these problems because of their
superior cardioprotection, allowing for lower vol-
umes and asanguineous delivery. This study was
designed to examine both intermittent and continu-
ous hyperpolarized and depolarized cardioplegia
over prolonged periods of ischemia.
Recovery of systolic function with intermittent-
infusion pinacidil. With intermittent infusion,
pinacidil cardioplegia showed a trend toward im-
proved functional recovery, but this was not statis-
tically different from control. This is in direct con-
trast to our previous results that looked at shorter
intervals of ischemia in which PCO cardioplegia
always resulted in improved postischemic recov-
ery.10-13 There are several possible explanations for
pinacidil’s failure to provide adequate myocardial
protection.
The loss of pinacidil’s cardioprotective effects
with prolonged ischemia may be related to the
prolonged and recurrent electrical activity typical of
PCO cardioplegia. However, this hypothesis was
refuted by the fact that the addition of procaine to
all pinacidil infusions eliminated all electrical activ-
ity but did not improve functional recovery. This is
consistent with our previous observations15 and can
be explained by the fact that the oxygen require-
ments needed to maintain electrical activity com-
prise less than 1% of the total basal oxygen con-
sumption of the heart.25
Another possibility is that pinacidil does not
result in hyperpolarized arrest in this model. How-
ever, a previous study26 that examined changes in
membrane potential in isolated myocyte prepara-
tions exposed to PCOs clearly demonstrated that
hyperpolarization occurs. However, it is possible
Fig. 3. Reperfusion coronary flow. All results are ex-
pressed as mean 6 SEM. Baseline is before ischemia is
begun. *Significantly increased flow compared with base-
line (p , 0.001, one-way repeated measures analysis of
variance).
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that pinacidil’s membrane hyperpolarization is not
maintained over longer ischemic periods. Further
investigation is necessary to clarify this issue.
Finally, it is possible that PCO membrane hyper-
polarization does not produce an energy-sparing
state as originally postulated. A recent study in our
laboratory supports this hypothesis. Reperfusion
myocardial oxygen consumption in hearts arrested
with pinacidil cardioplegia was found to be higher
than those arrested with potassium cardioplegia.27
Thus PCOs may convey their benefit via ionic (i.e.,
prevention of calcium overload) rather than meta-
bolic mechanisms.27 Over short periods, this ionic
benefit may be sufficient to provide improved sys-
tolic recovery despite ongoing metabolic demand.
Recovery of systolic function with continuous-
infusion pinacidil. When the same agents were
given as continuous cardioplegia, the results were
strikingly different. The enhanced functional recov-
ery in the control group over its intermittent equiv-
alent was expected because there was a continuous,
albeit slow, delivery of substrate (Fig. 2). However,
the delivery of St. Thomas’ Hospital solution as
continuous cardioplegia provided negligible myo-
cardial protection and was no better than the con-
tinuous control infusion of Krebs-Henseleit solu-
tion alone. In contrast, pinacidil demonstrated a
significant improvement in its cardioprotective
capacity when applied as continuous cardioplegia.
Although the same molar amount of cardioplegic
solution was delivered to the myocardium regard-
less of the infusion method, the slower continuous
infusion may have provided a steadier supply of
substrate than higher-flow intermittent infusions.
Additionally, continuous slow infusion may avoid
myocardial toxicity by providing a continuous
“washout” of toxic metabolites that is not as
efficient with periodic bolus infusions. Moreover,
during intermittent infusion, there may have been
a less effective delivery of cardioplegic solution to
the myocardium because of the shunting of solu-
tion away from the capillary network as a result of
the higher flow rates. Finally, continuous infusion
may have produced a more constant state of
hyperpolarization that would prevent calcium
overload and other ionic abnormalities associated
with depolarized potentials.
Postischemic recovery of diastolic properties.
Because this model incorporates a wide range of
volumes to establish systolic and diastolic pressure-
volume regressions, changes in compliance were
examined by comparing changes in the integrated
diastolic pressure–volume curves (Table II). Pinaci-
dil, in all doses, demonstrated protective effects on
diastolic properties, which were similar to the St.
Thomas’ Hospital solution groups. This is in agree-
ment with our previous work.10-13
Postreperfusion arrhythmias. PCOs have been
shown to be proarrhythmic.12, 27 By decreasing ac-
tion potential duration and therefore refractory
period, these agents are thought to provoke reen-
trant ventricular arrhythmias, which represents a
potential drawback of this class of drugs. In this
study, however, pinacidil did not significantly in-
crease the incidence of ventricular fibrillation. It is
possible that the antiarrhythmic effect of procaine
was responsible for the distinct lack of PCO-induced
ventricular fibrillation. Although further studies are
needed to confirm this hypothesis, sodium channel
blockade may emerge as an essential additive to
PCO cardioplegia.
Coronary flow. Pinacidil was associated with in-
creased, prolonged reperfusion coronary blood flow
when compared with St. Thomas’ Hospital solution
(Fig. 3), which reconfirms previous results from our
laboratory.13 The increase in reperfusion coronary
blood flow continued for the first 10 minutes of
reperfusion before returning to baseline. The
method of delivery did not alter this effect. The
reasons for this hyperemic response may be due to
several factors including the known vasodilatory
effect of pinacidil on vascular smooth muscle,28
improved endothelial protection,29 or a greater ox-
ygen debt during ischemia.27
Although the continuous and intermittent pinaci-
dil groups demonstrate a similar reperfusion coro-
nary blood flow profile, ventricular recovery of
developed pressure was significantly enhanced only
in the continuous group. In agreement with other
studies,30, 31 our study suggests the cardioprotective
effect of pinacidil is not related to its vasodilatory
effect.
Advantages and disadvantages of the blood-per-
fused isolated heart Langendorff model. The ad-
vantages and drawbacks concerning this model have
been previously described.12, 13 The more physio-
logic nature of this model is a distinct advantage
over nonparabiotic and crystalloid-perfused models.
However, care should be taken in extrapolating
results from in vitro studies to the clinical setting. To
determine the clinical feasiblility of pinacidil cardio-
plegia, in vivo studies are clearly needed.
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Summary
The method of delivery appeared to play a pivotal
role in the ability of pinacidil to protect the heart
during prolonged crossclamping. Pinacidil was inef-
fective as an intermittent-infusion cardioplegic
agent. The role of pinacidil in future myocardial
protection strategies will require further investiga-
tion into its dependency on continuous infusion and
its ability to minimize myocardial metabolism during
global ischemia.
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